UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 45

Sortiert nach

Extensions to the Visual Predictive Check to facilitate model performance evaluation

Journal of pharmacokinetics and pharmacodynamics, 2008-04, Vol.35 (2), p.185-202

2008

Link zum Volltext

Verfügbarkeit prüfen

Incorporating Receptor Theory in Mechanism-Based Pharmacokinetic-Pharmacodynamic (PK-PD) Modeling

DRUG METABOLISM AND PHARMACOKINETICS, 2009-01, Vol.24 (1), p.3-15

2009

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetic-Pharmacodynamic Model for the Reversal of Neuromuscular Blockade by Sugammadex

Anesthesiology (Philadelphia), 2009, Vol.110 (1), p.95-105

2009

Link zum Volltext

Verfügbarkeit prüfen

Exposure–Response Modeling and Simulation of Progression‐Free Survival and Adverse Events of Sorafenib Treatment in Patients With Advanced Thyroid Cancer

Clinical and translational science, 2019-09, Vol.12 (5), p.459-469

2019

Link zum Volltext

Verfügbarkeit prüfen

Population pharmacokinetics of regorafenib in solid tumours: Exposure in clinical practice considering enterohepatic circulation and food intake

British journal of clinical pharmacology, 2020-12, Vol.86 (12), p.2362-2376

2020

Link zum Volltext

Verfügbarkeit prüfen

Assessment of the safe and efficacious dose of the selective progesterone receptor modulator vilaprisan for the treatment of patients with uterine fibroids by exposure–response modelling and simulation

British journal of clinical pharmacology, 2022-02, Vol.88 (2), p.734-741

2022

Link zum Volltext

Verfügbarkeit prüfen

Clinical Pharmacokinetics and Pharmacodynamics of the Selective Progesterone Receptor Modulator Vilaprisan: A Comprehensive Overview

Clinical pharmacokinetics, 2022-01, Vol.61 (1), p.1-16

2022

Link zum Volltext

Verfügbarkeit prüfen

Phase 1 dose-escalation and pharmacokinetic study of regorafenib in paediatric patients with recurrent or refractory solid malignancies

European journal of cancer (1990), 2021-08, Vol.153, p.142-152

2021

Link zum Volltext

Verfügbarkeit prüfen

Changes in GABAA receptor properties in amygdala kindled animals: In vivo studies using [11C]flumazenil and positron emission tomography

Epilepsia (Copenhagen), 2009-01, Vol.50 (1), p.88-98

2009

Link zum Volltext

Verfügbarkeit prüfen

Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research

Trends in pharmacological sciences (Regular ed.), 2008-04, Vol.29 (4), p.186-191

2008

Link zum Volltext

Verfügbarkeit prüfen

The virtue of translational PKPD modeling in drug discovery: selecting the right clinical candidate while sparing animal lives

Drug discovery today, 2013-09, Vol.18 (17-18), p.853-862

2013

Link zum Volltext

Verfügbarkeit prüfen

Mechanism-based pharmacokinetic -pharmacodynamic modeling : Biophase distribution, receptor theory, and dynamical systems analysis

Annual review of pharmacology and toxicology, 2007-01, Vol.47 (1), p.357-400

2007

Link zum Volltext

Verfügbarkeit prüfen

Regorafenib plus nivolumab in patients with mismatch repair-proficient/microsatellite stable metastatic colorectal cancer: a single-arm, open-label, multicentre phase 2 study

EClinicalMedicine, 2023-04, Vol.58, p.101917-101917, Article 101917

2023

Link zum Volltext

Verfügbarkeit prüfen

Predicting human exposure of active drug after oral prodrug administration, using a joined in vitro/in silico–in vivo extrapolation and physiologically-based pharmacokinetic modeling approach

Journal of pharmacological and toxicological methods, 2013-05, Vol.67 (3), p.203-213

2013

Link zum Volltext

Verfügbarkeit prüfen

Systemic and direct nose-to-brain transport pharmacokinetic model for remoxipride after intravenous and intranasal administration

Drug metabolism and disposition, 2011-12, Vol.39 (12), p.2275

2011

Link zum Volltext

Verfügbarkeit prüfen

Translational pharmacokinetic modeling of fingolimod (FTY720) as a paradigm compound subject to sphingosine kinase-mediated phosphorylation

Drug metabolism and disposition, 2014-09, Vol.42 (9), p.1367

2014

Link zum Volltext

Verfügbarkeit prüfen

Characterization and Prediction of Cardiovascular Effects of Fingolimod and Siponimod Using a Systems Pharmacology Modeling Approach

The Journal of pharmacology and experimental therapeutics, 2017-02, Vol.360 (2), p.356

2017

Link zum Volltext

Verfügbarkeit prüfen

Population Pharmacokinetic Analysis for Simultaneous Determination of B max and K D In Vivo by Positron Emission Tomography

Molecular imaging and biology, 2005-11, Vol.7 (6), p.411-421

2005

Link zum Volltext

Verfügbarkeit prüfen

Mechanism-based PK–PD model for the prolactin biological system response following an acute dopamine inhibition challenge: quantitative extrapolation to humans

Journal of pharmacokinetics and pharmacodynamics, 2012-10, Vol.39 (5), p.463-477

2012

Link zum Volltext

Verfügbarkeit prüfen

Physiologically Based Pharmacokinetic Modeling of Glycyrrhizic Acid, a Compound Subject to Presystemic Metabolism and Enterohepatic Cycling

Toxicology and applied pharmacology, 2000-02, Vol.162 (3), p.177-188

2000

Link zum Volltext

Verfügbarkeit prüfen

Predicting human exposure of active drug after oral prodrug administration, using a joined in vitro/in silicoain vivo extrapolation and physiologically-based pharmacokinetic modeling approach

Journal of pharmacological and toxicological methods, 2013-06, Vol.67 (3), p.203-213

2013

Link zum Volltext

Verfügbarkeit prüfen

Changes in GABA A receptor properties in amygdala kindled animals: In vivo studies using [ 11 C]flumazenil and positron emission tomography

Epilepsia (Copenhagen), 2009-01, Vol.50 (1), p.88-98

2009

Link zum Volltext

Verfügbarkeit prüfen

Development of longitudinal PET studies for experimental animal models

Journal of Cerebral Blood Flow & Metabolism, 2005-08, Vol.25 (S1), p.S602-S602

2005

Link zum Volltext

Verfügbarkeit prüfen

Population pharmacokinetic analysis for simultaneous determination of B (max) and K (D) in vivo by positron emission tomography

Molecular imaging and biology, 2005-11, Vol.7 (6), p.411-421

2005

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 45

Suche als RSS-Feed

Aktive Filter

ThemaAdult

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(45)
Mit Volltextzugriff
(42)

Publikationsform

Artikel
(44)
Buchkapitel
(1)

Sprache

Englisch
(45)
Japanisch
(9)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Extensions to the Visual Predictive Check to facilitate model performance evaluation

Incorporating Receptor Theory in Mechanism-Based Pharmacokinetic-Pharmacodynamic (PK-PD) Modeling

Pharmacokinetic-Pharmacodynamic Model for the Reversal of Neuromuscular Blockade by Sugammadex

Exposure–Response Modeling and Simulation of Progression‐Free Survival and Adverse Events of Sorafenib Treatment in Patients With Advanced Thyroid Cancer

Population pharmacokinetics of regorafenib in solid tumours: Exposure in clinical practice considering enterohepatic circulation and food intake

Assessment of the safe and efficacious dose of the selective progesterone receptor modulator vilaprisan for the treatment of patients with uterine fibroids by exposure–response modelling and simulation

Clinical Pharmacokinetics and Pharmacodynamics of the Selective Progesterone Receptor Modulator Vilaprisan: A Comprehensive Overview

Phase 1 dose-escalation and pharmacokinetic study of regorafenib in paediatric patients with recurrent or refractory solid malignancies

Changes in GABAA receptor properties in amygdala kindled animals: In vivo studies using [11C]flumazenil and positron emission tomography

Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research

The virtue of translational PKPD modeling in drug discovery: selecting the right clinical candidate while sparing animal lives

Mechanism-based pharmacokinetic -pharmacodynamic modeling : Biophase distribution, receptor theory, and dynamical systems analysis

Regorafenib plus nivolumab in patients with mismatch repair-proficient/microsatellite stable metastatic colorectal cancer: a single-arm, open-label, multicentre phase 2 study

Predicting human exposure of active drug after oral prodrug administration, using a joined in vitro/in silico–in vivo extrapolation and physiologically-based pharmacokinetic modeling approach

Systemic and direct nose-to-brain transport pharmacokinetic model for remoxipride after intravenous and intranasal administration

Translational pharmacokinetic modeling of fingolimod (FTY720) as a paradigm compound subject to sphingosine kinase-mediated phosphorylation

Characterization and Prediction of Cardiovascular Effects of Fingolimod and Siponimod Using a Systems Pharmacology Modeling Approach

Population Pharmacokinetic Analysis for Simultaneous Determination of B max and K D In Vivo by Positron Emission Tomography

Mechanism-based PK–PD model for the prolactin biological system response following an acute dopamine inhibition challenge: quantitative extrapolation to humans

Physiologically Based Pharmacokinetic Modeling of Glycyrrhizic Acid, a Compound Subject to Presystemic Metabolism and Enterohepatic Cycling

Predicting human exposure of active drug after oral prodrug administration, using a joined in vitro/in silicoain vivo extrapolation and physiologically-based pharmacokinetic modeling approach

Regorafenib plus nivolumab in patients with mismatch repair-proficient/microsatellite stable metastatic colorectal cancer: a single-arm, open-label, multicentre phase 2 studyResearch in context

Changes in GABA A receptor properties in amygdala kindled animals: In vivo studies using [ 11 C]flumazenil and positron emission tomography

Development of longitudinal PET studies for experimental animal models

Population pharmacokinetic analysis for simultaneous determination of B (max) and K (D) in vivo by positron emission tomography

Aktive Filter

Suchergebnisse filtern